Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Essential Hypertension
NCT00667719Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of aliskiren, amlodipine and hydrochlorothiazide in essential hypertension, sponsored by Novartis. Primary endpoint: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death at 54 weeks. Started Jun 2008; status: completed.
02
Drugs
aliskirenamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00667719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667719.